Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: while there are promising developments like ramping up MAGiC catheter production and GenesisX system expansion, financial performance in Q1 2026 was weak with declining revenues and increased losses. The Q&A reveals confidence in future growth, yet lacks concrete timelines and details, which could cause investor hesitation. Given the absence of a market cap and the mixed sentiment, the stock price is likely to remain stable, resulting in a neutral prediction.
Key Financial Performance
Revenue for Q1 2026 $6.3 million, a decrease from $7.5 million in Q1 2025. The decline was attributed to the transition from the Johnson & Johnson ecosystem, which impacted recurring revenue.
System Revenue for Q1 2026 $1.3 million, a decrease from $2 million in Q1 2025. This reflects revenue recognition on the installation of the Genesis system and partial revenue recognition of other ancillary systems.
Recurring Revenue for Q1 2026 $5 million, a decrease from $5.5 million in Q1 2025. The decline was due to the transition from the Johnson & Johnson ecosystem.
Gross Margin for Q1 2026 60% of revenue. Recurring revenue gross margin was 66%, and system gross margin was 39%. No specific year-over-year comparison was provided.
Operating Expenses for Q1 2026 $9.8 million, including $3.1 million in noncash charges. Adjusted operating expenses were $6.7 million, similar to the prior year's adjusted operating expenses of $6.8 million.
Operating Loss for Q1 2026 $6 million, compared to $5.9 million in Q1 2025. The increase was due to the transition challenges and investments in new product rollouts.
Net Loss for Q1 2026 $5.9 million, compared to $5.8 million in Q1 2025. The slight increase was attributed to similar factors as the operating loss.
Adjusted Operating Loss for Q1 2026 $2.9 million, compared to $2.7 million in Q1 2025. The increase was due to the transition challenges and investments in new product rollouts.
Adjusted Net Loss for Q1 2026 $2.8 million, compared to $2.6 million in Q1 2025. The increase was due to the transition challenges and investments in new product rollouts.
Negative Free Cash Flow for Q1 2026 $3.5 million, compared to $1.8 million in Q1 2025. The increase was due to investments in inventory and other operational needs.
Cash and Cash Equivalents as of March 31, 2026 $14.6 million, with no debt. This reflects the company's efforts to maintain a clean balance sheet despite ongoing investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Regulatory Approvals: Received 4 U.S. FDA approvals for a surgical robot, therapeutic and diagnostic catheters, and a digital surgery cockpit. Also received approvals in Europe and China.
MAGiC Cardiac Ablation Catheter: First proprietary therapeutic catheter approved by FDA for arrhythmia patients with complex congenital heart disease. Initial procedures in U.S. hospitals have been successful.
GenesisX Robotic System: New robotic system launched, compatible with existing catheter labs without construction. Expected to establish at least 5 active programs this year.
Synchrony Digital Surgery Cockpit: Received FDA clearance and shipped first systems. Expected to generate $3 million in revenue this year.
Transition from Johnson & Johnson: Transitioning away from dependency on Johnson & Johnson catheters, impacting recurring revenue temporarily.
Expansion in Europe: Received a $100,000 order for disposables from a single hospital in Europe for a month's worth of procedures.
Manufacturing Ramp-Up: Production of MAGiC catheters expected to reach 500 units per month by year-end. Efforts underway to expand production capacity and redundancy.
Recurring Revenue Model: Initial U.S. MAGiC procedures generating $5,000-$8,000 per procedure in disposable revenue.
Acquisition of Robocath: Acquired Robocath to complement robotic mechanisms for endovascular device navigation.
AI and Automation: Developing AI features for decision support and automated navigation software for robotic procedures.
Future Innovations: Showcased a wireless, battery-operated, mobile version of GenesisX robot at a recent conference.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Manufacturing Challenges: The company faces challenges in ramping up manufacturing to meet the high demand for its new MAGiC catheter. Additionally, there are catheter shortages, and efforts to expand production capacity and redundancy are ongoing.
Transition from Legacy Business: The transition away from Johnson & Johnson's ecosystem is described as 'messy,' creating headwinds in reported financials and operational challenges during the shift to the new disposable business model.
Financial Pressures: Revenue for the first quarter of 2026 decreased compared to the prior year, and the company reported operating and net losses. Negative free cash flow also increased compared to the previous year.
Dependency on New Product Success: The company's future growth heavily depends on the successful adoption and scaling of its new products, including GenesisX and Synchrony. Any delays or issues in adoption could adversely impact financial performance.
Economic and Operational Risks: The company is balancing multiple operational and commercial activities simultaneously, including integrating Robocath and advancing R&D efforts, which could strain resources and execution capabilities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company reiterates its revenue guidance for the year, expecting double-digit revenue growth with annual revenue surpassing $40 million. Revenue is projected to ramp up sequentially each quarter, with the third and fourth quarters expected to exceed $10 million each.
Recurring Revenue Growth: Recurring revenue is expected to grow significantly, with the majority of it contributing to the bottom line. The transition from the Johnson & Johnson ecosystem to the new disposable business model is expected to be substantially completed by the end of the year.
MAGiC Catheter Rollout: The MAGiC catheter is being rolled out gradually in the U.S. and Europe, with production expected to reach 500 catheters per month by the end of the year. The company anticipates a robust recurring revenue model from this product.
GenesisX Robotic System: The company expects to establish at least 5 active GenesisX programs this year, with initial adopters demonstrating the technology's accessibility and performance.
Synchrony Revenue: The company is confident in achieving $3 million in revenue from Synchrony this year, with multiple systems already ordered and shipped.
Future Innovations: The company is advancing efforts in AI, automation, and robotics, including a fully wireless and mobile version of the GenesisX robot and decision support AI features for Synchrony. These innovations are expected to drive future growth.
Robocath Acquisition: The acquisition of Robocath is expected to complement the company's robotic solutions and enable advancements in remote, automated, and fully robotic treatment of stroke and cardiovascular disease.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the adoption and utilization of the MAGiC catheter portfolio?
A:MAGiC adoption is currently limited by production capacity. Sites fall into three categories: those transitioning fully to MAGiC, those using both MAGiC and J&J catheters, and those still using only J&J catheters but planning to transition in the coming months. Manufacturing is ramping up, and as capacity increases, more sites are expected to fully transition to MAGiC.
Q:What assumptions are included in the guidance for reaching $40 million in revenue, and how confident are you in manufacturing improvements?
A:The guidance assumes reaching 500 catheters per month by year-end, which would significantly increase disposable revenue. The recurring revenue is expected to approach $10 million per quarter as catheter manufacturing ramps up. Despite a weak quarter for system sales, there is confidence in the pipeline and backlog for Genesis and GenesisX systems.
Q:Can you quantify the impact of the disposable business in the quarter?
A:MAGiC and MAGiC Sweep contributed very little revenue in the quarter due to limited production in January and February, as the manufacturing process was being improved. Production increased in March, but revenue recognition will occur in subsequent months. Johnson & Johnson's limited catheter supply has created headwinds, but the MAGiC portfolio is expected to overshadow these pressures in the coming quarters.
Q:What is the feedback and outlook for the GenesisX system?
A:GenesisX is designed to work with non-integrated X-rays, expanding its potential market. The first GenesisX system was sold and shipped under the historical model with integrated X-ray. Efforts are ongoing to demonstrate compatibility with major X-ray manufacturers, which will open new opportunities. Early adopters are expected to help validate this model.
Q:What mapping platforms are being used with MAGiC, and could there be turbulence as the J&J catheter supply relationship ends?
A:MAGiC is predominantly used with Abbott's EnSite X mapping system, with some compatibility with Carto and MicroPort's Columbus system (available in Europe and China). The transition away from J&J catheters is expected to proceed smoothly due to these integrations.
Q:What is the progress on PFA development and the opportunity in ambulatory surgery centers (ASCs)?
A:PFA development is progressing with collaborations, including CardioFocus, to integrate MAGiC with PFA generators. Regulatory engagement has begun in Europe. The ASC setting is a growing opportunity, particularly for procedures like PVCs where the robot's safety and stability are advantageous. A GenesisX installation in an ASC is anticipated this year to demonstrate its value.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or quantitative details on when the first GenesisX orders for non-integrated X-ray compatibility would be finalized and installed. Additionally, while they expressed confidence in the ASC opportunity, they did not provide concrete data or timelines for growth in this area.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA approval
FDA clearance
GenesisX
MAGiC procedure
RD
Stereotaxis history
Sync
System
acquisition Robocath
afternoon Stereotaxis
approval Europe
approval MAGiC
automation
benefit
catheter month
connectivity
dependency
direction
example
experience
generation
heart disease
innovation
intelligence
legacy
manufacturer
month FDA
noncash charge
path
patient
physician procedure
progress shoot
ramp
start
success
surgery cockpit
transformation
vision
work
STXS Transcript
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals: while there are promising developments like ramping up MAGiC catheter production and GenesisX system expansion, financial performance in Q1 2026 was weak with declining revenues and increased losses. The Q&A reveals confidence in future growth, yet lacks concrete timelines and details, which could cause investor hesitation. Given the absence of a market cap and the mixed sentiment, the stock price is likely to remain stable, resulting in a neutral prediction.
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call reveals mixed elements: a strong product pipeline with FDA approvals and optimistic future revenue growth, but current challenges include negative free cash flow, operating losses, and manufacturing issues. The Q&A highlights stable revenue from existing products and positive feedback on new launches, but also concerns about manufacturing constraints and management's vague responses on key issues. These factors balance each other out, leading to a neutral sentiment.
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call presented mixed signals: while product development with GenesisX and new catheters is promising, financials show consistent losses and a negative cash flow. The Q&A reveals a cautious approach to new launches and regulatory approvals, indicating uncertainty. No strong catalysts like partnerships or guidance changes were mentioned. Therefore, the stock is likely to remain stable in the short term.
Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals: while product development and business updates show promise, especially in Europe, financial performance is concerning with declining system revenue and increasing operating losses. The Q&A reveals positive reception of new products but highlights uncertainties in U.S. regulatory approvals and market adoption challenges. The lack of a share repurchase program and structural challenges further dampen sentiment. Overall, the mixed guidance and financials, coupled with regional uncertainties, suggest a neutral stock price movement.
STXS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
